0001628280-24-000698.txt : 20240105 0001628280-24-000698.hdr.sgml : 20240105 20240105173336 ACCESSION NUMBER: 0001628280-24-000698 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240103 FILED AS OF DATE: 20240105 DATE AS OF CHANGE: 20240105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wise John Drayton CENTRAL INDEX KEY: 0001930805 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 24517651 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 4 1 wk-form4_1704494003.xml FORM 4 X0508 4 2024-01-03 0 0001104506 INSMED Inc INSM 0001930805 Wise John Drayton 700 US HIGHWAY 202/206 BRIDGEWATER NJ 08807 0 1 0 0 Chief Commercial Officer 1 Stock Option (right to buy) 2024-01-03 4 M 0 20071 19.11 A 124055 D Stock Option (right to buy) 2024-01-03 4 S 0 20071 29.19 D 103984 D Common Stock 2024-01-04 4 A 0 12873 A 116857 D Common Stock 2024-01-05 4 S 0 1167 29.32 D 115690 D Stock Option (right to buy) 19.11 2024-01-03 4 M 0 20071 0 D 2024-02-10 Common Stock 20071 0 D Stock Option (right to buy) 29.13 2024-01-04 4 A 0 63560 0 A 2034-01-04 Common Stock 63560 63560 D This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Includes 1,303 shares acquired through the Company's 2018 Employee Stock Purchase Plan. This is the weighted average sales price representing 20,071 shares sold at prices ranging from $28.915 to $29.39 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the date of the grant. Each Restricted Stock Unit was received as a grant on January 4, 2024, for no consideration. Shares sold to satisfy withholding tax obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Stock options granted under the Company's 2013 Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant. Stock options granted under the Company's Amended and Restated 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary date of the date of grant. /s/ John Drayton Wise, by Michael A. Smith as Attorney-in-fact 2024-01-05